ghk-cu fda approved status Committee Votes to Ease Restrictions on Six Peptides EllieMD | KLOW Injection

The clinical diagnosis of obstructive Meibomian gland dysfunction (OMGD) should be considered when the standard, traditional, first line treatment modalities for Meibomian gland dysfunction have failed to provide sufficient relief of symptoms, the patients condition progressively worsens with continued loss of Meibomian glands as seen on meibography, or the patient continues to have recurrent infections of his/her eyelids (styes, hordeola, chalazia, cellulitis, etc.)

Products formulated within this range help preserve the skin barrier and peptide stability

No mutagenicity, carcinogenicity, or reproductive toxicity has been demonstrated

Net per kit: 10 mg BPC-157 + 10 mg TB-500 (each filled to approximately 104% of label)